Lumida
/AMPH
⌘K
Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

AMPH
$22.01USD+0.59%+0.13 today

MARKET CAP

937.7M

P/E (TTM)

13.3x

FWD P/E

DAY RANGE

$22 – $22

52W RANGE

$17
$31

AI Summary

Stalk
StalkMedium

AMPH is in a Stage 1 early consolidation after a terminal decline, trading in a tight range around its short EMAs and 50 DMA. Mean-reversion eligibility and strong free-cash-flow metrics support a tactical bounce from the well-defended demand zone, consistent with the Free Cash Flow + Buybacks strategy’s emphasis on high-quality entry points. However, indicators and volume remain neutral with no clear timing edge. Execution should be patient for pullback-based entries near support.

  • Proprietary products to drive revenue: pipeline share from 37% to 85% by 2026
  • Reported Q2 net revenue of $183.9M (+5% YoY), surpassing $179.7M estimate
  • BAQSIMI® down 3% and Primatene MIST® down 8% signal revenue headwinds
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$437.8M$499.0M$644.4M$732.0M$719.9M
YoY %+25.1%+14.0%+29.1%+13.6%-1.7%
P / Sales2.6x3.0x5.1x2.6x1.8x
EV / Sales2.9x3.1x6.3x3.6x2.7x
Gross Profit, Adj.$199.7M$248.9M$351.1M$373.9M$356.1M
YoY %+39.3%+24.6%+41.1%+6.5%-4.8%
Margin %45.6%49.9%54.5%51.1%49.5%
EV / Gross Profit6.3x6.2x11.5x7.0x5.5x
EBITDA, Adj.$96.4M$132.3M$235.0M$258.4M$197.1M
YoY %+166.8%+37.2%+77.7%+9.9%-23.7%
Margin %22.0%26.5%36.5%35.3%27.4%
EV / EBITDA13.1x11.6x17.1x10.2x10.0x
EBIT$69.9M$107.5M$197.0M$205.4M$140.4M
YoY %+538.0%+53.8%+83.2%+4.3%-31.7%
Margin %16.0%21.5%30.6%28.1%19.5%
EV / EBIT18.0x14.3x20.5x12.8x14.0x
Net Income$62.1M$91.4M$137.5M$159.5M$98.1M
YoY %+4327.4%+47.1%+50.5%+16.0%-38.5%
Net Margin14.2%18.3%21.3%21.8%13.6%
EPS (GAAP)$1.25$1.74$2.60$3.06$2.03
YoY %+4066.7%+39.2%+49.4%+17.7%-33.7%